Randomized trial assesses worse outcomes for EGFR amplification in metastatic non-small cell lung cancer, suggesting a need for tailored treatment strategies.
Key Points
This research investigates the impact of EGFR amplification on the outcomes of patients with EGFR-mutated metastatic non-small cell lung cancer receiving osimertinib.
Included 473 patients with stage IV NSCLC and specific EGFR mutations receiving first-line osimertinib.
Utilized next-generation sequencing to assess EGFR amplification, defined as EGFR copy number ≥6.
Conducted multivariable analysis to evaluate associations between EGFR amplification and clinical outcomes.
Patients with EGFR amplification had a shorter median progression-free survival (mPFS) of 11.6 months compared to 19.0 months for non-amplified patients (HR 1.77, p < 0.0001).
EGFR amplification was associated with a higher rate of TP53 co-mutations (80% vs 55%, p < 0.001).
In the ex19del subgroup, EGFR amplification led to mPFS of 14.2 months versus 20.2 months for non-amplified (HR 2.01, p < 0.001).